ABSTRACT
The development of donor-specific antibodies (DSA) after lung transplantation is common and results in adverse outcomes. In kidney transplantation, Belatacept has been associated with a lower incidence of DSA, but experience with Belatacept in lung transplantation is limited. We conducted a 2-center pilot randomized controlled trial of de novo immunosuppression with Belatacept after lung transplantation to assess the feasibility of conducting a pivotal trial. Twenty-seven participants were randomized to Control (Tacrolimus, Mycophenolate Mofetil, and prednisone, n = 14) or Belatacept-based immunosuppression (Tacrolimus, Belatacept, and prednisone until day 89 followed by Belatacept, Mycophenolate Mofetil, and prednisone, n = 13). All participants were treated with rabbit anti-thymocyte globulin for induction immunosuppression. We permanently stopped randomization and treatment with Belatacept after 3 participants in the Belatacept arm died compared to none in the Control arm. Subsequently, 2 additional participants in the Belatacept arm died for a total of 5 deaths compared to none in the Control arm (log rank p = 0.016). We did not detect a significant difference in DSA development, acute cellular rejection, or infection between the 2 groups. We conclude that this investigational regimen using Belatacept after lung transplantation is associated with significantly increased mortality.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form and declare the following: MA is a member of the Scientific Advisory Board and has received an honorarium from One Lambda, Inc and has received grant funding from NHLBI and Bristol Myers Squibb; CB has received grant funding from NHLBI; PD has received grant funding from NHLBI; RH has received grant funding from NHLBI and Bristol Myers Squibb and Mallinckrodt, RH has received consulting fees from CareDx, Natera, and Transmedics; HH has received grant funding from NHLBI, Bristol Myers Squibb, CareDx, CSL Behring, consulting fees from Atara Biotherapeutics and Regeneron Pharmaceuticals, speaker fees from Boehringer Ingelheim and serves on an advisory board for CareDx; DK has received grant funding and consulting fees from Compass Therapeutics and has pending patent application number 15/611,557; KS has received grant funding from NHLBI; BM has received grant funding from NHLBI; AG has received grant funding from NIAID and NHLBI, Royalties from UCLA School of Medicine and Quark Biopharmaceuticals; there are no other relationships or activities that could appear to have influenced the submitted work.
Clinical Trial
NCT03388008, IND138662
Funding Statement
This study was funded by a grant from the National Heart, Lung, and Blood Institute (HL138186) and Bristol Myers Squibb through an Investigator Sponsored Research program (IM103-387).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the Washington University in St. Louis Human Research Protection Office and by the Houston Methodist Hospital Institutional Review Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
